Product Development
MTY's product development is focused on acute inflammatory conditions that represent largely unmet medical needs. Our objective is to develop Cuprindo™ as anti-inflammatory therapy or co-therapy in acute conditions such as distal proctitis, acute cholecystitis and acute vascular inflammation. In addition, we are actively looking to acquire complimentary technologies in the areas of anti-inflammatory reformulation and re-profiling.
| Drug Candidate |
Indication |
Pre-
clinical |
Phase 1 |
Phase 2 |
Phase 3 |
| Cuprindo™ topical |
Acute
Cholecystitis |
|
|
|
|
| Cuprindo™ topical |
Distal
proctitis |
|
|
|
|
| Cuprindo™ topical |
Inflammation of
the gallbladder |
|
|
|
|
| Cuprindo™ oral |
Acute vascular
inflammation |
|
|
|
|